Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erie Indemnity stock logo
ERIE
Erie Indemnity
$357.48
-1.3%
$386.44
$199.49
$420.34
$18.70B0.4895,709 shs44,817 shs
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$13.40
+0.1%
$13.70
$9.25
$14.30
$19.42B1.0816.06 million shs10.30 million shs
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$27.46
+1.4%
$27.94
$25.92
$34.65
$16.18B0.472.62 million shs2.43 million shs
Ventas, Inc. stock logo
VTR
Ventas
$49.70
-0.3%
$45.91
$39.33
$50.99
$20.17B1.332.07 million shs1.49 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erie Indemnity stock logo
ERIE
Erie Indemnity
-1.30%-1.37%-11.62%-14.04%+66.15%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
+0.15%-3.74%-4.63%-0.74%+17.34%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
+1.37%+0.18%-1.89%-9.58%-18.73%
Ventas, Inc. stock logo
VTR
Ventas
-0.28%-1.11%+4.76%+11.89%+7.14%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Erie Indemnity stock logo
ERIE
Erie Indemnity
1.2179 of 5 stars
0.02.04.20.00.01.72.5
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
4.9725 of 5 stars
3.44.03.33.62.62.53.1
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
4.8546 of 5 stars
3.43.02.53.73.21.72.5
Ventas, Inc. stock logo
VTR
Ventas
3.4993 of 5 stars
1.34.02.53.62.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erie Indemnity stock logo
ERIE
Erie Indemnity
N/AN/AN/AN/A
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
2.75
Moderate Buy$15.3014.18% Upside
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
2.80
Moderate Buy$43.0056.59% Upside
Ventas, Inc. stock logo
VTR
Ventas
2.69
Moderate Buy$51.463.54% Upside

Current Analyst Ratings

Latest RPRX, VTR, HBAN, and ERIE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2024
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$28.00
5/30/2024
Ventas, Inc. stock logo
VTR
Ventas
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$46.00 ➝ $49.00
5/28/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$16.00 ➝ $18.00
5/16/2024
Ventas, Inc. stock logo
VTR
Ventas
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$47.00 ➝ $51.00
4/22/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
4/22/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$15.00
4/12/2024
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $38.00
4/9/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.00 ➝ $16.00
4/8/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$14.00 ➝ $16.00
4/8/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$14.00 ➝ $16.00
4/5/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$14.00 ➝ $15.00
(Data available from 6/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erie Indemnity stock logo
ERIE
Erie Indemnity
$3.27B5.72$9.47 per share37.75$31.79 per share11.25
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$10.84B1.79$2.02 per share6.64$11.74 per share1.14
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$2.36B6.97$4.63 per share5.93$16.88 per share1.63
Ventas, Inc. stock logo
VTR
Ventas
$4.50B4.47$3.26 per share15.26$23.72 per share2.10

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erie Indemnity stock logo
ERIE
Erie Indemnity
$446.06M$9.2638.6031.64N/A14.26%29.60%19.88%7/25/2024 (Estimated)
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$1.95B$1.1112.079.442.4815.86%11.99%1.05%7/19/2024 (Confirmed)
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$1.13B$1.3420.496.243.5435.70%22.94%13.78%8/13/2024 (Estimated)
Ventas, Inc. stock logo
VTR
Ventas
-$40.97M-$0.19N/A14.842.58-1.58%-0.75%-0.29%8/1/2024 (Estimated)

Latest RPRX, VTR, HBAN, and ERIE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/19/2024N/A
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.29N/A-$0.29N/AN/AN/A  
5/9/2024Q1 2024
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.96$0.98+$0.02$1.95$671.45 million$568.00 million    
4/25/2024Q1 2024
Erie Indemnity stock logo
ERIE
Erie Indemnity
$2.33$2.38+$0.05$2.38$835.61 million$880.70 million    
4/19/2024Q1 24
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.25$0.28+$0.03$0.30$1.74 billion$2.85 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Erie Indemnity stock logo
ERIE
Erie Indemnity
$5.101.43%+7.24%55.08%35 Years
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
$0.624.63%+1.10%55.86%N/A
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
$0.843.06%+38.67%62.69%4 Years
Ventas, Inc. stock logo
VTR
Ventas
$1.803.62%-5.64%N/A N/A

Latest RPRX, VTR, HBAN, and ERIE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2024
Erie Indemnity stock logo
ERIE
Erie Indemnity
Quarterly$1.27501.34%7/8/20247/9/20247/23/2024
5/14/2024
Ventas, Inc. stock logo
VTR
Ventas
quarterly$0.453.75%7/1/20247/1/20247/18/2024
4/19/2024
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
quarterly$0.15504.67%6/17/20246/17/20247/1/2024
4/17/2024
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
Quarterly$0.213.04%5/16/20245/17/20246/14/2024
3/12/2024
Ventas, Inc. stock logo
VTR
Ventas
quarterly$0.454.13%3/28/20244/1/20244/18/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erie Indemnity stock logo
ERIE
Erie Indemnity
N/A
1.33
1.33
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
0.88
0.88
0.88
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
0.62
12.52
12.52
Ventas, Inc. stock logo
VTR
Ventas
1.43
0.63
0.63

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Erie Indemnity stock logo
ERIE
Erie Indemnity
33.67%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
80.72%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
54.35%
Ventas, Inc. stock logo
VTR
Ventas
94.18%

Insider Ownership

CompanyInsider Ownership
Erie Indemnity stock logo
ERIE
Erie Indemnity
45.79%
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
0.89%
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
18.90%
Ventas, Inc. stock logo
VTR
Ventas
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Erie Indemnity stock logo
ERIE
Erie Indemnity
6,55652.30 million28.35 millionOptionable
Huntington Bancshares Incorporated stock logo
HBAN
Huntington Bancshares
19,9551.45 billion1.44 billionOptionable
Royalty Pharma plc stock logo
RPRX
Royalty Pharma
51597.44 million484.52 millionOptionable
Ventas, Inc. stock logo
VTR
Ventas
486404.77 million400.73 millionOptionable

RPRX, VTR, HBAN, and ERIE Headlines

Recent News About These Companies

Ventas (NYSE:VTR) Issues FY 2024 Earnings Guidance
Ventas (NYSE:VTR) PT Raised to $49.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Erie Indemnity logo

Erie Indemnity

NASDAQ:ERIE
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. It provides issuance and renewal services; sales related services, including agent compensation, and sales and advertising support services; underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. The company was incorporated in 1925 and is based in Erie, Pennsylvania.
Huntington Bancshares logo

Huntington Bancshares

NASDAQ:HBAN
Huntington Bancshares Incorporated operates as the bank holding company for The Huntington National Bank that provides commercial, consumer, and mortgage banking services in the United States. The company offers financial products and services to consumer and business customers, including deposits, lending, payments, mortgage banking, dealer financing, investment management, trust, brokerage, insurance, and other financial products and services. It also provides 24-hour grace, asterisk-free checking, money scout, $50 safety zone, standby cash, early pay, instant access, savings goal getter, and Huntington heads up; digitally powered consumer and business financial solutions to consumer lending, regional banking, branch banking, and wealth management customers; direct and indirect consumer loans, as well as dealer finance loans and deposits; and private banking, wealth management and legacy planning through investment and portfolio management, fiduciary administration and trust, institutional custody, and full-service retail brokerage investment services. The company offers equipment financing, asset-based lending, distribution finance, structured lending, and municipal financing solutions, as well as Huntington ChoicePay. In addition, it offers lending, liquidity, treasury management and other payment services, and capital markets; government and non-profits, healthcare, technology and telecommunications, franchises, financial sponsors, and global services; and corporate risk management, institutional sales and trading, debt and equity issuance, and additional advisory services. The company offers its products through a network of channels, including branches and ATMs, online and mobile banking, and through customer call centers to customers in middle market banking, corporate, specialty, and government banking, asset finance, commercial real estate banking, and capital markets. The company was founded in 1866 and is headquartered in Columbus, Ohio.
Royalty Pharma logo

Royalty Pharma

NASDAQ:RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Ventas logo

Ventas

NYSE:VTR
Ventas Inc. (NYSE: VTR) is a leading S&P 500 real estate investment trust focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. The Company's growth is fueled by its senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas leverages its unmatched operational expertise, data-driven insights from its Ventas Operational InsightsTM platform, extensive relationships and strong financial position to achieve its goal of delivering outsized performance across approximately 1,400 properties. The Ventas portfolio is composed of senior housing communities, outpatient medical buildings, research centers and healthcare facilities in North America and the United Kingdom. The Company benefits from a seasoned team of talented professionals who share a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.